Autoimmune Disease Diagnostics Market to Grow with a CAGR of 6.37% through 2028
Rising disease prevalence, government initiatives, an
expanding product portfolio, and global expansion is expected to drive the
Global Autoimmune Disease Diagnostics Market growth in the forecast period,
2024-2028.
According to TechSci Research report, “Autoimmune
Disease Diagnostics Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Autoimmune
Disease Diagnostics Market stood at USD 5.02 billion in 2022 and is anticipated
to grow with a CAGR of 6.37% in the forecast period, 2024-2028. This can be
attributed to collaborations and mergers. Collaboration and mergers within the
healthcare sector have also contributed to market growth. Companies often join
forces to combine expertise, share resources, and develop more comprehensive
diagnostic solutions. These collaborations enable the creation of innovative
diagnostics that can address the complexity of autoimmune diseases effectively.
Moreover, patient-centric diagnostics prioritize the
patient's experience and preferences. This trend emphasizes communication,
education, and shared decision-making between patients and healthcare
providers. Autoimmune disease diagnostics are evolving to involve patients in
the diagnostic process, leading to more informed decisions and improved
adherence to treatment plans.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Autoimmune Disease Diagnostics Market.”
The market is
being driven by factors such as the increasing prevalence of autoimmune
diseases, heightened awareness regarding disease diagnosis, and advancements in
technology. The rising incidence of autoimmune disorders is expected to boost
the growth of the autoimmune disease diagnostics market. According to the 2020
Atlas of Multiple Sclerosis Report, over 2.8 million people worldwide, with
approximately 1 million in the United States, are currently living with
multiple sclerosis. Europe faced a significant burden of autoimmune diseases,
with the highest prevalence of multiple sclerosis in 2020, estimated at 2.5
million people globally. Rheumatoid arthritis affects around two million
people, and psoriasis, one of the most common autoimmune disorders, is believed
to impact between 2% and 3% of the general population. Increased awareness of
autoimmune disorders through research, education, support, and advocacy
initiatives is a significant driver of rising diagnosis rates.
Furthermore, the
escalating global burden of autoimmune diseases, along with increasing health
and disease awareness, fuels the demand for early disease detection
diagnostics, driving market growth. For example, the American Autoimmune
Related Disease Association (AARDA) designates March as Autoimmune Disease
Awareness Month (ADAM) to raise awareness and support the eradication of
autoimmune diseases. The American Kidney Fund (AKF) launched an educational
campaign in February 2021 focused on lupus nephritis, a kidney condition caused
by lupus, providing crucial information to patients about symptoms, diagnosis,
and treatment. In September 2021, Scipher Medicine partnered with Ventegra Inc.
to offer customers access to Scipher's PrismRA liquid molecular signature test,
aiding in the personalized treatment of rheumatoid arthritis patients (RA).
Despite these promising factors, challenges such as delayed result turnaround,
the necessity for multiple diagnostic tests, high costs, reimbursement
concerns, and regulatory uncertainties may hinder market growth.
The Global Autoimmune
Disease Diagnostics Market is segmented into component, test type, disease type,
end user, regional distribution, and company.
Based on end
user, hospitals and clinics are poised to dominate the global autoimmune
disease diagnostics market due to their pivotal role in healthcare
infrastructure. These healthcare facilities serve as primary points of care for
patients seeking diagnosis and treatment. With the increasing prevalence of
autoimmune diseases and the need for accurate and timely diagnostics, hospitals
and clinics become central hubs for autoimmune disease testing. They offer a
wide range of diagnostic services, access to specialized medical professionals,
and state-of-the-art equipment necessary for comprehensive autoimmune disease
diagnosis. Moreover, the trend toward collaborative and multidisciplinary
approaches to healthcare further solidifies the position of hospitals and
clinics as key players in the autoimmune disease diagnostics market, as they
provide integrated care and access to a wide array of diagnostic tools,
including advanced imaging, genetic testing, and biomarker-based assays,
essential for accurate diagnosis and effective disease management.
Based on region,
Asia Pacific segment is expected to grow during the forecast period, driven by
the increasing incidence of autoimmune diseases and a growing awareness
regarding their diagnosis. Furthermore, market players are taking strategic
measures, research efforts are on the rise, and healthcare infrastructure is
being developed, all of which contribute to the market's growth. According to a
June 2022 report from Janssen Asia Pacific, a subsidiary of Johnson &
Johnson Pte. Ltd., autoimmune, inflammatory, and respiratory conditions like
rheumatoid arthritis, psoriasis, and inflammatory bowel disease are on the rise
in the Asia Pacific region. The area already grapples with the highest global
burden of chronic obstructive pulmonary disease (COPD), as well as the highest
prevalence of systemic lupus erythematosus (SLE) in China and Southeast Asia.
Consequently, there is likely to be an increased demand for diagnostics in the
years to come.
Major companies
operating in Global Autoimmune Disease Diagnostics Market are:
- Abbott Laboratories
- Siemens Healthineers AG
- Roche Diagnostics Corp
- Beckman Coulter Inc
- SQI Diagnostics Inc
- EUROIMMUN Medizinische Labordiagnostika AG
- Aesku Diagnostics GmbH & Co KG
- INOVA Diagnostics Inc
- Crescendo Bioscience LLC
- bioMerieux SA
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The Global
Autoimmune Disease Diagnostics Market is witnessing a transformation driven by
emerging trends that focus on precision medicine, biomarker discovery,
point-of-care testing, artificial intelligence, telemedicine, multiplex
testing, patient-centric diagnostics, global expansion, and ongoing research
and development. These trends hold the promise of improving the accuracy,
accessibility, and personalization of autoimmune disease diagnostics,
ultimately enhancing patient care and outcomes. As technology continues to
advance and the understanding of autoimmune diseases deepens, the future of
autoimmune disease diagnostics appears promising, offering hope for better
disease management and improved quality of life for patients,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Autoimmune Disease Diagnostics Market By Component
(Instruments, Reagents, Consumables), By Test Type (Routine Laboratory Tests,
Inflammatory Markers, Antibodies & Immunologic Tests, Others), By Disease
Type (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease
Diagnostics) By Systemic Autoimmune Diseases (Rheumatoid Arthritis, Ankylosing
Spondylitis, Systemic Lupus Erythematosus, Others), By Localized Autoimmune
Diseases (Multiple Sclerosis, Type 1 Diabetes, Hashimoto’s Thyroiditis,
Others), By End User (Hospitals & Clinics, Diagnostic Centers, Others), By
Region, By Competition Forecast & Opportunities, 2018-2028F”,
has evaluated the future growth potential of Global Autoimmune Disease
Diagnostics Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Autoimmune Disease
Diagnostics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue,
Suite 300,
New York,
United
States- 10170
M:
+13322586602
Email: [email protected]
Website: https://www.techsciresearch.com